SG10202100422VA - Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy - Google Patents
Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapyInfo
- Publication number
- SG10202100422VA SG10202100422VA SG10202100422VA SG10202100422VA SG10202100422VA SG 10202100422V A SG10202100422V A SG 10202100422VA SG 10202100422V A SG10202100422V A SG 10202100422VA SG 10202100422V A SG10202100422V A SG 10202100422VA SG 10202100422V A SG10202100422V A SG 10202100422VA
- Authority
- SG
- Singapore
- Prior art keywords
- lymphocytes
- therapy
- activating
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/14—Colloidal silica, e.g. dispersions, gels, sols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201613772 | 2016-08-10 | ||
GBGB1701827.6A GB201701827D0 (en) | 2017-02-03 | 2017-02-03 | Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202100422VA true SG10202100422VA (en) | 2021-02-25 |
Family
ID=59569333
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202100422VA SG10202100422VA (en) | 2016-08-10 | 2017-08-09 | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy |
SG11201901129XA SG11201901129XA (en) | 2016-08-10 | 2017-08-09 | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901129XA SG11201901129XA (en) | 2016-08-10 | 2017-08-09 | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy |
Country Status (10)
Country | Link |
---|---|
US (2) | US11007217B2 (en) |
EP (1) | EP3496728B1 (en) |
JP (2) | JP2019529354A (en) |
KR (1) | KR102362797B1 (en) |
CN (1) | CN109789159A (en) |
AU (1) | AU2017309968B2 (en) |
CA (1) | CA3033422A1 (en) |
ES (1) | ES2879881T3 (en) |
SG (2) | SG10202100422VA (en) |
WO (1) | WO2018029247A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201904334D0 (en) * | 2019-03-28 | 2019-05-15 | Sisaf Ltd | Carrier system for preparing herbaceous extracts |
CN116462202A (en) * | 2023-03-21 | 2023-07-21 | 东沃同泰(凤城)生物工程有限公司 | Carboxylic acid modified silica aerogel, preparation method and application thereof, and drug delivery system |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2588109B2 (en) | 1993-03-19 | 1997-03-05 | 日本臓器製薬株式会社 | Painkillers |
NL9400189A (en) | 1994-02-07 | 1995-09-01 | Bio Pharma Sciences Bv | Stabilized orthosilicic acid-containing preparation, a method for its preparation and a biological preparation. |
EP1371289A1 (en) | 2002-03-20 | 2003-12-17 | Bio Minerals N.V. | Choline-silicic acid complex |
US8173176B2 (en) * | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
EP2125847B1 (en) | 2007-02-06 | 2015-06-17 | Medical Research Council | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation |
US9889151B2 (en) | 2007-10-15 | 2018-02-13 | Hs Pharmaceuticals, Llc | Silicate containing compositions and methods of treatment |
JP2009155262A (en) * | 2007-12-26 | 2009-07-16 | Lion Corp | Antiviral agent |
KR100950548B1 (en) * | 2008-01-10 | 2010-03-30 | 연세대학교 산학협력단 | A porous hollow silica nanoparticle, preparation method thereof, drug carrier and pharmacetical composition comprising the same |
DE102008033175A1 (en) * | 2008-07-15 | 2010-01-21 | Merck Patent Gmbh | Silica nanoparticles and their use for vaccination |
EP2151466A1 (en) * | 2008-08-01 | 2010-02-10 | SiNatur GmbH | Biologically active silicic acid |
US20160287717A1 (en) * | 2013-09-18 | 2016-10-06 | Stc.Unm | Core and Surface Modification of Mesoporous Silica Nanoparticles to Achieve Cell Specific Targeting In Vivo. |
GB201402672D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Materials and methods relating to stabilised polymeric silicate compositions |
CN104825488B (en) * | 2015-05-25 | 2018-04-24 | 厦门大学 | One kind loads arsenical and preparation method and application |
-
2017
- 2017-08-09 SG SG10202100422VA patent/SG10202100422VA/en unknown
- 2017-08-09 KR KR1020197006227A patent/KR102362797B1/en active IP Right Grant
- 2017-08-09 AU AU2017309968A patent/AU2017309968B2/en active Active
- 2017-08-09 JP JP2019507262A patent/JP2019529354A/en active Pending
- 2017-08-09 ES ES17749718T patent/ES2879881T3/en active Active
- 2017-08-09 US US16/324,401 patent/US11007217B2/en active Active
- 2017-08-09 WO PCT/EP2017/070183 patent/WO2018029247A1/en unknown
- 2017-08-09 EP EP17749718.7A patent/EP3496728B1/en active Active
- 2017-08-09 CN CN201780055709.3A patent/CN109789159A/en active Pending
- 2017-08-09 CA CA3033422A patent/CA3033422A1/en active Pending
- 2017-08-09 SG SG11201901129XA patent/SG11201901129XA/en unknown
-
2021
- 2021-04-19 US US17/233,802 patent/US11980637B2/en active Active
-
2022
- 2022-08-22 JP JP2022132004A patent/JP2022180360A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11007217B2 (en) | 2021-05-18 |
AU2017309968A1 (en) | 2019-03-28 |
EP3496728B1 (en) | 2021-05-26 |
ES2879881T3 (en) | 2021-11-23 |
AU2017309968B2 (en) | 2022-12-08 |
JP2019529354A (en) | 2019-10-17 |
CA3033422A1 (en) | 2018-02-15 |
CN109789159A (en) | 2019-05-21 |
US11980637B2 (en) | 2024-05-14 |
US20190192555A1 (en) | 2019-06-27 |
KR20190040228A (en) | 2019-04-17 |
EP3496728A1 (en) | 2019-06-19 |
WO2018029247A1 (en) | 2018-02-15 |
US20210338710A1 (en) | 2021-11-04 |
KR102362797B1 (en) | 2022-02-15 |
JP2022180360A (en) | 2022-12-06 |
SG11201901129XA (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1259388A1 (en) | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma | |
IL251774A0 (en) | Methods and compositions for dosing in adoptive cell therapy | |
EP3414311A4 (en) | Compositions and methods for use in surface decontamination | |
HK1243942A1 (en) | Sunitinib formulations and methods for use thereof in treatment of glaucoma | |
ZA201604810B (en) | Surface treatment of particles and their use | |
ZA201604860B (en) | Surface treatment of particles and their use | |
EP3100043A4 (en) | System and methods for estimation of mechanical properties and size of light-scattering particles in materials | |
EP3487974A4 (en) | Device and related compositions and methods for use in surface decontamination | |
ZA201704726B (en) | Peptides and their use in the treatment of skin | |
HK1254254A1 (en) | Methods and compositions for the detection of calr mutations in myeloproliferative diseases | |
GB201517571D0 (en) | Improvements relating to scatter in x-ray apparatus and methods of their use | |
EP3419656A4 (en) | Neoantigen compositions and methods of using the same in immunooncotherapy | |
PL3157354T3 (en) | Composition in the form of compacted particles and use thereof | |
PL3129057T3 (en) | Glycolipids and pharmaceutical compositions thereof for use in therapy | |
EP3433035A4 (en) | Compositions and methods of use thereof in sandcasting | |
HUE058749T2 (en) | Compositions and methods for use in the treatment of homocystinuria | |
PL3233233T3 (en) | Defoaming compositions comprising amphiphilic particles and methods of using the same | |
SG10202100422VA (en) | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy | |
ZA201705400B (en) | Compositions containing arsenic and their use in methods of treatment | |
EP3497243A4 (en) | Cell therapy compositions and methods of use thereof | |
IL251957A0 (en) | Il-12 compositions and methods of use in hematopoietic recovery | |
PT3408287T (en) | Gdf15 in glaucoma and methods of use thereof | |
IL249860A0 (en) | Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer | |
GB201701827D0 (en) | Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy | |
PT2958959T (en) | Hydrophobisation agent and use thereof for the surface treatment of particles of inorganic matter |